123ArticleOnline Logo
Welcome to 123ArticleOnline.com!

ALL >> Business >> View Article

Harver Group Investing Heavily In Potential Cancer Cure

By Author: Harver Group
Total Articles: 26

Jul. 22, 2013 - CHUO-KU, Japan -- Harvard Bioscience Inc. (HBIO) has received little attention for their research from the medical establishment or from educational institutions. While posting consistent growth and a strong customer base, shareholders have not seen much profit to date due to operating losses from the company´s Regenerative Medical Device division also known as Harvard Apparatus Regenerative Technology.

“We believe that Harvard Bioscience Inc. is a solid investment now” said Peter Anderson Senior Vice President of Mergers and Acquisitions at Harver Group, “before Harvard Apparatus Regenerative Technology is given an initial public offering”.

Head of Investment Analysis, Mr. Nathan Marx said “Removing Harvard Apparatus from their balance sheets should lead to an increase in valuation of at least 50% in the short term and potentially 100% in the long term if shareholder friendly policies are enacted. We expect the IPO to happen within four months”.

Harvard Apparatus Regenerative Technology is pursing ground breaking research; they are preforming clinical trials of their cure for trachea cancer. The trials have produced very exciting results, with a high survival rate for a typically fatal form of cancer. They’ve created scaffolding, which in conjunction with cells from the patient construct a new trachea. This technology has further applications, for lung and heart, heart valve, liver, and kidney transplants as well as esophageal cancer.

Both the President and CFO of Harvard Bioscience Inc. will be leaving to run Harvard Apparatus Regenerative Technology. We believe that this indicates that a sale of Harvard Bioscience is in the works, due to the fact that the President and CFO along with other members of management own 14% of the company. Management will likely maximize value, and sell the company for at least $10 a share. We are recommending our clients to move on Harvard Bioscience Inc. as soon as possible and we will bring more news on Harvard Apparatus Research Technology IPO as we receive it.

Total Views: 74Word Count: 321See All articles From Author

Business Articles

1. Advantages And Disadvantages Of Concrete Staining
Author: Ben Lager

2. What To Look For When Hiring An Ocean Freight Shipping Company
Author: William Santos

3. Top 4 Advantages Of Concrete Coating
Author: Ben Lager

4. Centrifugal Blower Manufacturer In India|centrifugal Blower Fan
Author: sara

5. Building A Modern Architecture Homes- Planning And Concept
Author: Leila Adam

6. Thorough Proofreading Finesses Documents, Raises The Organization’s Reputation
Author: NetZealous LLC, DBA TrainHR

7. Design And Build Contractor Singapore – Get The Best Services From Interior Renovation Contractor!
Author: James Han

8. Meishen–a Bright Star In Magnesium Oxide Industry
Author: hu Allen

9. Grow Customer Base And Market Presence With Pharmacist Email Lists For Your Business Campaign
Author: Adam Tyson

10. Adapt New Forms Of B2b Communication With Infection Control Directors Mailing List
Author: Andrew Rayel

11. Moby Wrap Baby Carrier
Author: babycarriersaustralia21

12. Care For Your Deck
Author: Blue Star Carpentry has been specializing in custom decks for over a decade. When you sit outside wi

13. How Does A Small B2b Company Increase The sales?
Author: Mohit Yadev

14. Latest Job Vacancies In India
Author: careersresults

15. Why Are Aap And Congress Supporters Opposing A Tax Reform Like The Gst? Are They Anti-nationals?
Author: Mohit Yadev

Login To Account
Login Email:
Password:
Forgot Password?
New User?
Sign Up Newsletter
Email Address: